U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H28N4O11
Molecular Weight 608.5528
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EDOTECARIN

SMILES

OCC(CO)NN1C(=O)C2=C(C1=O)C3=C(N([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C5=C3C=CC(O)=C5)C6=C2C7=C(N6)C=C(O)C=C7

InChI

InChIKey=QMVPQBFHUJZJCS-NTKFZFFISA-N
InChI=1S/C29H28N4O11/c34-7-10(8-35)31-33-27(42)20-18-13-3-1-11(37)5-15(13)30-22(18)23-19(21(20)28(33)43)14-4-2-12(38)6-16(14)32(23)29-26(41)25(40)24(39)17(9-36)44-29/h1-6,10,17,24-26,29-31,34-41H,7-9H2/t17-,24-,25+,26-,29-/m1/s1

HIDE SMILES / InChI
Edotecarin (J-107088 or [6-N-(1-hydroxymethyl-2-hydroxy)ethylamino-12,13-dihydro-2,10-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carb azo le-5,7(6H)-dione]) is a DNA topoisomerase I inhibitor. The antitumor activity of edotecarin has been tested in vitro and in vivo, and inhibition of tumor growth has been observed in breast, cervix, pharynx, lung, prostate, colon, gastric, and hepatic cancer models. Banyu Pharmaceutical Co Ltd and Pfizer Inc were developing edotecarin for the potential treatment of solid tumors. Edotecarin development has been discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed

Sample Use Guides

The recommended Phase II dose of edotecarin is 13 mg/m(2) once every 21 days.
Route of Administration: Intravenous
Name Type Language
EDOTECARIN
INN   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
Edotecarin [WHO-DD]
Common Name English
edotecarin [INN]
Common Name English
PF-804950
Code English
J-107088
Code English
EDOTECARIN [USAN]
Common Name English
EDOTECARIN [MI]
Common Name English
12-.BETA.-D-GLUCOPYRANOSYL-2,10-DIHYDROXY-6-((1-HYDROXY-1-(HYDROXYMETHYL)ETHYL)AMINO)-12,13-DIHYDRO-6H-INDOLO(2,3-A)PYRROLO(3,4-C)CARBAZOLE-5,7-DIONE
Systematic Name English
5H-INDOLO(2,3-A)PYRROLO(3,4-C)CARBAZOLE-5,7(6H)-DIONE, 12-.BETA.-D-GLUCOPYRANOSYL-12,13-DIHYDRO-2,10-DIHYDROXY-6-((2-HYDROXY-1-(HYDROXYMETHYL)ETHYL)AMINO)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C1904
Created by admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
Code System Code Type Description
FDA UNII
1V8X590XDP
Created by admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
PRIMARY
ChEMBL
CHEMBL435191
Created by admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
PRIMARY
NCI_THESAURUS
C2665
Created by admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
PRIMARY
INN
8246
Created by admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
PRIMARY
SMS_ID
100000089430
Created by admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
PRIMARY
MERCK INDEX
m4830
Created by admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
PRIMARY Merck Index
DRUG BANK
DB04882
Created by admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
PRIMARY
EPA CompTox
DTXSID40870123
Created by admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
PRIMARY
MESH
C121395
Created by admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
PRIMARY
CAS
174402-32-5
Created by admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
PRIMARY
PUBCHEM
9808998
Created by admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
PRIMARY
USAN
RR-32
Created by admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
PRIMARY
EVMPD
SUB25404
Created by admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
PRIMARY